Funding Rounds
PDC*line pharma

PDC*line pharma Series B (2024, $8M)

PDC*line pharma

Personalised therapeutic vaccine developer for colorectal cancer.

View Company Profile

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Stage: Series B

Raised Amount: $8.70M